In a non-comparative phase 2 trial of 84 patients with pretreated progressive metastatic pancreatic neuroendocrine tumours, 12-month progression-free survival was 80.5% with [177Lu]Lu-dota-tate vs 41.9% with sunitinib; one treatment-related leukaemia death occurred.
RCTn = 84
Baudin et al. [177Lu]Lu-dota-tate versus sunitinib in patients with metastatic progressive neuroendocrine tumours of the pancreas (OCLURANDOM): a randomised, controlled, phase 2 trial